HomeInsightsStock Comparison

Aspira Pathlab Diagnostics Ltd vs Maitreya Medicare Ltd Stock Comparison

Aspira Pathlab Diagnostics Ltd vs Maitreya Medicare Ltd Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

  • The Latest Trading Price of Aspira Pathlab & Diagnostics Ltd is ₹ 143.34 as of 29 Sep 10:20 . The P/E Ratio of Aspira Pathlab & Diagnostics Ltd changed from 43.3 on March 2025 to 0 on March 2026 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Maitreya Medicare Ltd changed from 30.8 on March 2024 to 0 on March 2026 . This represents a CAGR of -100.00% over 6 years The Market Cap of Aspira Pathlab & Diagnostics Ltd changed from ₹ 31.91 crore on March 2024 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 6 yearsThe Market Cap of Maitreya Medicare Ltd changed from ₹ 80.63 crore on March 2024 to ₹ 121.19 crore on March 2026 . This represents a CAGR of 7.03% over 6 years The revenue of Aspira Pathlab & Diagnostics Ltd for the Jun '25 is ₹ 5.36 crore as compare to the Mar '25 revenue of ₹ 5.91 crore. This represent the decline of -9.31% The revenue of Maitreya Medicare Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Aspira Pathlab & Diagnostics Ltd for the Jun '25 is ₹ 0.79 crore as compare to the Mar '25 ebitda of ₹ 1.05 crore. This represent the decline of -24.76% The ebitda of Maitreya Medicare Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Aspira Pathlab & Diagnostics Ltd changed from ₹ 0.05 crore to ₹ 0.42 crore over 5 quarters. This represents a CAGR of 448.81% The net profit of Maitreya Medicare Ltd changed from ₹ 0 crore to ₹ 0 crore over 5 quarters. This represents a CAGR of 0.0% The Dividend Payout of Aspira Pathlab & Diagnostics Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Maitreya Medicare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Aspira Pathlab & Diagnostics Ltd

  • Aspira Pathlab & Diagnostics Limited (ASDL) was incorporated in July, 1973.
  • ASDL is a leading pathology specialist, with Pan-India presence.
  • It offer pathology and diagnostic services to individual patients, hospitals, other healthcare providers, and businesses.
  • The Company, with a wider presence in Maharashtra India, enjoys a loyal customer base, that reflects on its strength as a brand, providing superior diagnostic testing and services. Presently, Company is engaged into the business of running, owning, managing and administering Diagnostics Centers.
  • Its principal activities consist of pathology investigation services, radiology investigation services and other related healthcare services at Diagnostic Centres in Mumbai. ASDL ideology is founded on technological supremacy, patient centric approach, and dependable diagnostic results.

About Maitreya Medicare Ltd

  • Maitreya Medicare Limited was originally incorporated as Maitreya Medicare Private Limited' at Surat Gujarat, vide a Certificate of Incorporation dated March 28, 2019, issued by the Registrar of Companies, Central Registration Centre (CRC).
  • Thereafter, name of the Company was changed to Maitreya Medicare Limited' and a fresh Certificate of Incorporation was issued by the RoC on March 30, 2023.
  • Since then, Company engages in providing healthcare services and products. The Company was founded by Dr. Narendra Singh Tanwar, an eminent and highly skilled cardiologist who has more than 20 years of experience in healthcare industry.
  • The Company is a growing organization that aims at strengthening and establishing itself as foremost healthcare services provider.
  • It has a team of medical practitioners who ensures that patients get the quality healthcare services.

FAQs for the comparison of Aspira Pathlab & Diagnostics Ltd and Maitreya Medicare Ltd

Which company has a larger market capitalization, Aspira Pathlab & Diagnostics Ltd or Maitreya Medicare Ltd?

Market cap of Aspira Pathlab & Diagnostics Ltd is 129 Cr while Market cap of Maitreya Medicare Ltd is 97 Cr

What are the key factors driving the stock performance of Aspira Pathlab & Diagnostics Ltd and Maitreya Medicare Ltd?

The stock performance of Aspira Pathlab & Diagnostics Ltd and Maitreya Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aspira Pathlab & Diagnostics Ltd and Maitreya Medicare Ltd?

As of October 25, 2026, the Aspira Pathlab & Diagnostics Ltd stock price is INR ₹126.05. On the other hand, Maitreya Medicare Ltd stock price is INR ₹144.55.

How do dividend payouts of Aspira Pathlab & Diagnostics Ltd and Maitreya Medicare Ltd compare?

To compare the dividend payouts of Aspira Pathlab & Diagnostics Ltd and Maitreya Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions